Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.6
5.4
Journals
Marine Drugs
Special Issues
Bioactive Metabolites from Marine-Derived Penicillium or Aspergillus Species
share announcement

Bioactive Metabolites from Marine-Derived Penicillium or Aspergillus Species

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Pharmacology".

Deadline for manuscript submissions: 15 May 2024 | Viewed by 3130

Special Issue Editor

Dr. Zhongbin Cheng

E-Mail
Guest Editor
School of Pharmaceutical Sciences, Hainan University, Kaifeng, China
Interests: natural product chemistry; bioactivity; marine; fungi; penicillium; aspergillus

Special Issue Information

Dear Colleagues,

Filamentous fungal strains, particularly species belonging to Penicillium or Aspergillus, are a vital source of structurally diverse molecules with pharmaceutical potential. Since the miraculous medicine penicillin G was discovered from P. notatum in 1928, the discovery of potent cholesterol-lowering agents, including compactin from P. citrinum, lovastatin from P. compactum and A. terreus, and the immunosuppressant mycophenolic acid from P. brevicompactum, has proven that these two genera are potential sources of bioactive compounds.

In recent decades, with the development of separation and structural identification techniques, improvements in our ocean-going and deep-diving capabilities, as well as the invention of advanced sampling and cultivation equipment, numerous marine-derived Penicillium or Aspergillus strains have been discovered; these have provided us human beings with many molecules possessing fascinating biological and pharmacological properties.

In this Special Issue, research papers and pertinent reviews focusing on topics such as the isolation and structural elucidation, chemical synthesis, biosynthesis, and pharmaceutical mechanisms of bioactive metabolites discovered from marine-derived Penicillium or Aspergillus species are welcome.

Dr. Zhongbin Cheng
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marine-derived fungi
  • penicillium
  • aspergillus
  • bioactivity
  • isolation and structural elucidation
  • chemical synthesis
  • biosynthesis
  • pharmaceutical mechanisms

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 1663 KiB  
Communication
Origin of the 6/5/6/5 Tetracyclic Cyclopiazonic Acids
by Wenyuan Zhang, Xuejian Jiang, Minjun Wang, Zhizhen Zhang and Nan Wang
Mar. Drugs 2024, 22(2), 74; https://doi.org/10.3390/md22020074 - 31 Jan 2024
Viewed by 1295
Abstract
The natural product α-cyclopiazonic acid (α-CPA) is a very potent Ca2+-ATPase inhibitor. The CPA family of compounds comprise over 80 chemical entities with at least five distinct skeletons. While α-CPA features a canonical 6/5/6/5/5 skeleton, the 6/5/6/5 skeleton is the most [...] Read more.
The natural product α-cyclopiazonic acid (α-CPA) is a very potent Ca2+-ATPase inhibitor. The CPA family of compounds comprise over 80 chemical entities with at least five distinct skeletons. While α-CPA features a canonical 6/5/6/5/5 skeleton, the 6/5/6/5 skeleton is the most prevalent among the CPA family. However, the origin of the unique tetracyclic skeleton remains unknown. The 6/5/6/5-type CPAs may derive from a precursor of acetoacetyl-l-tryptophan (AATrp) generated from a hypothetic thioesterase-like pathway. Alternatively, cleavage of the tetramic acid ring would also result in the formation of the 6/5/6/5 scaffold. Aspergillus oryzae HMP-F28 is a marine sponge-associated filamentous fungus known to produce CPAs that act as primary neurotoxins. To elucidate the origin of this subfamily of CPAs, we performed homologous recombination and genetic engineering experiments on strain HMP-F28. Our results are supportive of the ring cleavage pathway through which the tetracyclic 6/5/6/5-type CPAs are generated from 6/5/6/5/5-type pentacyclic CPAs. Full article
(This article belongs to the Special Issue Bioactive Metabolites from Marine-Derived Penicillium or Aspergillus Species)
►▼ Show Figures

Figure 1

15 pages, 5294 KiB  
Article
Rapid Discovery of Substances with Anticancer Potential from Marine Fungi Based on a One Strain–Many Compounds Strategy and UPLC-QTOF-MS
by Yu-Ting Wu, Xiao-Na Zhao, Pei-Xi Zhang, Cui-Fang Wang, Jing Li, Xiao-Yue Wei, Jia-Qi Shi, Wang Dai, Qi Zhang and Jie-Qing Liu
Mar. Drugs 2023, 21(12), 646; https://doi.org/10.3390/md21120646 - 18 Dec 2023
Cited by 1 | Viewed by 1581
Abstract
The secondary metabolites of marine fungi with rich chemical diversity and biological activity are an important and exciting target for natural product research. This study aimed to investigate the fungal community in Quanzhou Bay, Fujian, and identified 28 strains of marine fungi. A [...] Read more.
The secondary metabolites of marine fungi with rich chemical diversity and biological activity are an important and exciting target for natural product research. This study aimed to investigate the fungal community in Quanzhou Bay, Fujian, and identified 28 strains of marine fungi. A total of 28 strains of marine fungi were screened for small-scale fermentation by the OSMAC (One Strain-Many Compounds) strategy, and 77 EtOAc crude extracts were obtained and assayed for cancer cell inhibition rate. A total of six strains of marine fungi (P-WZ-2, P-WZ-3-2, P-WZ-4, P-WZ-5, P56, and P341) with significant changes in cancer cell inhibition induced by the OSMAC strategy were analysed by UPLC-QTOF-MS. The ACD/MS Structure ID Suite software was used to predict the possible structures with inhibitory effects on cancer cells. A total of 23 compounds were identified, of which 10 compounds have been reported to have potential anticancer activity or cytotoxicity. In this study, the OSMAC strategy was combined with an untargeted metabolomics approach based on UPLC-QTOF-MS to efficiently analyse the effect of changes in culture conditions on anticancer potentials and to rapidly find active substances that inhibit cancer cell growth. Full article
(This article belongs to the Special Issue Bioactive Metabolites from Marine-Derived Penicillium or Aspergillus Species)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop